OBJECTIVES To examine frailty transitions in Mexican American (MA) and European American (EA) older adults. DESIGN Longitudinal, observational cohort study. SETTING Socioeconomically diverse neighborhoods in San Antonio, Texas. PARTICIPANTS 312 MA and 285 EA community-dwelling older adults (65+) with frailty information at baseline (1992–96) and transition information at follow-up (2000–01) in the San Antonio Longitudinal Study of Aging (SALSA). MEASUREMENTS Five frailty characteristics (weight loss, exhaustion, weakness, slowness, and low physical activity), frailty score (0–5), and overall frailty state (non-frail = 0 characteristics, pre-frail = 1 or 2, frail = 3+) were assessed at baseline. Transitions (progressed, regressed, or no change) were assessed for frailty score and state. Odds ratios (OR) of progression and regression in individual characteristics were estimated using generalized estimating equations, adjusting for age, sex, ethnic group, socioeconomic status, comorbidity, diabetes, and follow-up interval. RESULTS Diabetes with macrovascular complications (OR=1.84, 95%CI: 1.02–3.33), fewer years of education (OR=0.96, 95%CI: 0.93–1.0) and follow-up interval (OR=1.3, 95%CI: 1.17–1.46) were significant predictors of progression in any frailty characteristic. Mortality increased by frailty state, and pre-frail individuals were more likely than frail to regress. CONCLUSION Diabetes with macrovascular complications and fewer years of education are important predictors of progression in any frailty characteristic. Because of increased risk of death compared with the non-frail state and the increased likelihood of regression compared with the frail state, the pre-frail state may be an optimal target for intervention.

Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. ASPREE will examine whether the potential primary prevention benefits of low dose aspirin outweigh the risks in older healthy individuals. Our primary hypothesis is that daily oral 100 mg enteric-coated aspirin will extend a composite primary endpoint termed ‘disability-free life’ including onset of dementia, total mortality, or persistent disability in at least one of the Katz Activities of Daily Living in 19,000 healthy participants aged 65 years and above (‘US minorities’) and 70 years and above (non ‘US minorities’). ASPREE is a double-blind, randomized, placebo-controlled trial of oral 100 mg enteric-coated acetyl salicylic acid (ASA) or matching placebo being conducted in Australian and US community settings on individuals free of dementia, disability and cardiovascular disease (CVD) events. Secondary endpoints are all-cause and cause specific mortality, fatal and non-fatal cardiovascular events, fatal and non-fatal cancer (excluding non-melanoma skin cancer), dementia, mild cognitive impairment, depression, physical disability, and clinically significant bleeding. To 20 September 2013 14383 participants have been recruited. Recruitment and study completion is anticipated in July 2014 and December 2018 respectively. In contrast to other aspirin trials that have largely focused on cardiovascular endpoints, ASPREE has a unique composite primary endpoint to better capture the overall risk and benefit of aspirin to extend healthy independent lifespan in older adults in the US and Australia.

These physical and biological findings suggest that the IL-10(tm/tm) mouse develops inflammation and strength decline consistent with human frailty at an earlier age compared to C57BL/6J control type mice. This finding provides rationale for the further development and utilization of the IL-10(tm/tm) mouse to study the biological basis of frailty.

Exercise provides a robust physiological stimulus that evokes cross-talk among multiple tissues that when repeated regularly (i.e., training) improves physiological capacity, benefits numerous organ systems, and decreases the risk for premature mortality. However, a gap remains in identifying the detailed molecular signals induced by exercise that benefits health and prevents disease. The Molecular Transducers of Physical Activity Consortium (MoTrPAC) was established to address this gap and generate a molecular map of exercise. Preclinical and clinical studies will examine the systemic effects of endurance and resistance exercise across a range of ages and fitness levels by molecular probing of multiple tissues before and after acute and chronic exercise. From this multi-omic and bioinformatic analysis, a molecular map of exercise will be established. Altogether, MoTrPAC will provide a public database that is expected to enhance our understanding of the health benefits of exercise and to provide insight into how physical activity mitigates disease.